Geneoscopy Inc., a St. Louis gastrointestinal health startup that has developed a test to screen for colon cancer, has raised $105 million in a Series C funding round. The new Series C funding will support the commercial launch of ColoSense, Geneoscopy’s at-home, stool-based screening test for colorectal cancer in those 45 years or older, as well as continued investment in Geneoscopy’s pipeline of diagnostic tests for inflammatory bowel disease…
